Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
T-DXd demonstrated promising intracranial activity in pretreated HER2-low ABC patients with active BMs. Further studies are needed to validate these results in larger cohorts. This trial is registered with ClinicalTrials.gov, NCT04420598.
Authors
- A Llombart-Cussac
- Daniel Alcalá-López (ORCID: https://orcid.org/0000-0003-2184-1346)
- Sònia Servitja (ORCID: https://orcid.org/0000-0001-6988-4519)
- Cristina Saavedra (ORCID: https://orcid.org/0000-0002-1063-2306)
- Adela Fernández-Ortega (ORCID: https://orcid.org/0000-0001-5921-0246)
- Sofía Braga (ORCID: https://orcid.org/0000-0002-3163-0174)
- Laia Garrigós
- Griselda Martrat
- María Gión (ORCID: https://orcid.org/0000-0002-6601-3360)
- Iris Teruel (ORCID: https://orcid.org/0000-0002-5563-6562)
- Juan de la Haba-Rodríguez (ORCID: https://orcid.org/0000-0001-5111-1702)
- Manuel Ruíz‐Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
- Jhudit Pérez‐Escuredo (ORCID: https://orcid.org/0009-0009-1691-1849)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Marta Vaz Batista (ORCID: https://orcid.org/0000-0001-5791-2092)
- Miguel Sampayo-Cordero (ORCID: https://orcid.org/0000-0003-1469-3410)
- José Manuel Pérez-García (ORCID: https://orcid.org/0000-0003-4238-2046)
- María Fernández (ORCID: https://orcid.org/0000-0002-4382-4726)
- Patricia Cortez
- A Martínez-Bueno
Institutions
- Universidad de Alcalá (ES)
- Instituto Cajal (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Instituto Oncológico Dr. Rosell (ES)
- Hospital Universitario Dexeus (ES)
- Hospital Prof. Dr. Fernando Fonseca (PT)
- MedSIR (Spain) (ES)
- Institut Català d'Oncologia (ES)
- Hospital Del Mar (ES)
- Badalona Serveis Assistencials (ES)
- Hospital Ruber Internacional (ES)
- Hospital Municipal de Badalona (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103699
- Citations
- 29
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 8.19
Funders
- AstraZeneca
- Daiichi Sankyo Europe